How the Austrian Covid PreS-RBD vaccine works which affects all variants
PreS-RBD is a new protein-subunit Covid vaccine developed by the University of Vienna that affects all variants. Here’s how it works.
Turn on notifications to receive updates on
There COVID-19 Pandemic it’s all but finished and they are still working on new ones vaccine candidatesamong those designed to hit all variants of the coronavirus SARS-CoV-2 and the so-called “universal”, Which may be able to block potential future variants and related viruses pandemic pathogen. Among the most interesting is the vaccine a protein subunits produced by French pharmaceutical / biotech companies LinKinVax and GTP Bioways, based on a monoclonal antibody designed to stimulate the dendritic cells of the immune system. Another very promising vaccine candidate is the PreS-RBD under development in Austria, which has shown in laboratory tests an induction of neutralizing (immunoglobulins IgG) higher than that of Covid vaccines already available and effective against all variants, including the “super mutated” Omicronknown for its evasive abilities and responsible for the current wave of infections.
The new Covid vaccine was developed by an international research team led by Austrian colleagues from the Center for Pathophysiology, Infectious Disease and Immunology of the Medical University of Vienna, which in close contact with colleagues from the Department of Clinical Immunology and Allergology of the Sechenov First Moscow State Medical University of Moscow (Russia), of the Karl Landsteiner University of Health Sciences, of the Department of Materials and Environmental Chemistry of the University of Stockholm (Sweden) and of numerous other research centers. Rodolf coordinated the new Covid vaccine with the aim of inducing thesterilizing immunity through through effective and long-lasting agents.
Unlike the already available Covid vaccines, which focus on protein S or Harpoon of SARS-CoV-2, the hook from the virus to bind to human cells, invade them and the disease exploits, the new Austrian drug is based on a recombinant fusion protein folded with two main components, which work in synergy to strengthen the immune response. The fusion protein consists of two receptor binding domains (RBD) of the SARS-CoV-2 coronavirus andPreS antigen And C-terminal hepatitis B (HBV), “which act as immunological vectors for each other”, reads instudio abstract. Come the LinKinVax, also the PreS-RBD is a protein subunit vaccine, a technology that has long been used for vaccines.
Fourth dose of Covid vaccine for everyone, Ema and Ecdc slow down: “It’s too early”
The combination of antigens was tested on animal models (rabbits) and produced a robust and specific immune response against RBD, inducing the formation of neutralizers that prevent the SARS-CoV-2 coronavirus from attaching to human cells (through the ACE-2 receptor) and actually prevent infection. The they explain that IgG induced by Covid vaccines a mRNA they are transitory, while those developed with the new vaccine are “long-lived”. In laboratory tests they can all be suitable and can be reacted against variants that can include Omicron, they also inhibited the link between RBD-2, so much so that the authors of the study believe the new vaccine to be those cured at risk of reinfection, due to ineffective against RBD. The antibody titers of the PreS-RBD vaccine were finally higher than those detected in cured and vaccinated with two doses of Covid vaccines already available.
“The PreS-RBD vaccine has the potential to induce sterilizing immunity to old and new variants of SARS-CoV-2 by preventing infection by disrupting viral replication and transmission by inhibiting cell virus entry,” he said. declared in the a Press release Professor Rudolf Valenta. “Our data gives us reason to hope that this protein-based vaccine antigen will be against all SARS-CoV-2 variants known to date, including Omicron,” explained the expert, adding that at the time in tests the production of eliminants “seems to be higher” than that of the vaccines already available. The details of the research “Vaccine based on folded RBD-PreS fusion protein with the potential to induce sterilizing immunity to SARS-CoV-2 variants”Were published in the scientific journal Allergy.
window._fpcmp.push(function(gdpr) { !function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}; if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0'; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)}(window, document,'script', 'https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '2062554930705272'); fbq('track', 'PageView'); //fbq('track', 'ViewContent'); //send custom checkpoints event (function () { var checkPoints = [10, 20, 40, 60, 90, 120, 180, 240, 300].sort(function(a, b) { return a - b; }); //seconds var checkPointIndex = 0; var f = function(){ var data = { instant: checkPoints[checkPointIndex] }; console.log("[FB PIXEL] send custom event ViewContentCheckPoint ", data, " on account " ,"2062554930705272" , " currentTime in seconds ", new Date().getTime() / 1000); fbq('trackCustom', 'ViewContentCheckPoint', data); checkPointIndex++; if(checkPointIndex < checkPoints.length) { setTimeout(f, (checkPoints[checkPointIndex] - checkPoints[checkPointIndex-1]) * 1000) } }; if(checkPoints.length){ setTimeout(f, checkPoints[checkPointIndex] * 1000) } })(); });